Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oral Care in connection with the acquisition of Dutch dental care provider De Tandartsengroep (DTG)
Mandate

Vinge advises Oral Care in connection with the acquisition of Dutch dental care provider De Tandartsengroep (DTG)

February 19, 2025 Banking and Finance Employment and Benefits M&A Intellectual Property Commercial Agreements

DTG operates 31 clinics and 8 dental laboratories in the Netherlands. Oral Care is a portfolio company of Axcel VI and operates a network of dental clinics in Sweden, Norway and the Netherlands. To support this expansion, Axcel VII is joining Axcel VI as a shareholder in Oral Care.

The transaction is subject to customary approval by the Dutch Health Care Authority and the Dutch Authority for Consumers and Markets (ACM).

Vinge's team consisted of Christina Kokko, Manon de Cooman, Gustav Wahlberg, Helena Liljenberg, Josef Groow (M&A), Alice Göransson (Employment Law), Avid Axelryd (Intellectual Property), Calle Tengwall Pagels, August Ahlin, Sara Jansson (Banking and Finance), Carla Håkansson, Katja Hägglund (Commercial Agreements), Frida Lansfjord, Jacob Guve, Alma Rotsman, Augus Olding (Assistants).

Read the client's press release here.

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

 Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026